

How to Cite:

Singh , V., Sawarkar, P., Parwe, S., & Sawarkar, G. (2022). Comparative evaluation of efficacy of Haridradigana Yoga Basti with Haridradigana Ghana Vati and Metformin in the management of diabetes mellitus type II (Prameha). *International Journal of Health Sciences*, 6(S2), 451–463. <https://doi.org/10.53730/ijhs.v6nS2.5026>

Comparative Evaluation of Efficacy of Haridradigana Yoga Basti with Haridradigana Ghana Vati and Metformin in the Management of Diabetes Mellitus Type II (Prameha) – A study Protocol

Varinder Singh

PG Scholar, Department of Panchakarma, Mahatma Gandhi Ayurved College Hospital & Research Centre, Salod (H.), Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra

Punam Sawarkar

Associate Professor, Department of Panchakarma , Mahatma Gandhi Ayurved College Hospital & Research Centre, Salod (H.), Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra

Shweta Parwe

Professor, Department of Panchakarma , Mahatma Gandhi Ayurved College Hospital & Research Centre, Salod (H.), Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra

Gaurav Sawarkar

Associate Professor, Department of Rachana Sharir, Mahatma Gandhi Ayurved College Hospital & Research Centre, Salod (H.), Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra

Abstract---*Prameha* is one of the very common ailment or disorder which people are facing from a period of time. It is increasing day by day and passing on from generation to generations. Because it is a disorder occurring due to changes in habits, diet and sedentary lifestyle. Basically, in this disorder there is involvement of vitiated *Vata* and *Kapha*. In this there is a *Avarana* of *Vata Dosha* on *Kapha Dosha*. For Vitiated *Vata Dosha Basti Karma* is considered as highly appreciable and effective and *Kapha-Ghana* herbs should be used as a medicinal purposes to counter Vitiated *Kapha Dosha*. In this study *Haridradi Gana* is selected for *Yoga Basti* as this *Gana* possess *Kapha ghana* properties. *Basti* procedure is selected as it is ultimate solution of vitiated *Vata Dosha*. Along with this, *Vati* prepared by same

International Journal of Health Sciences ISSN 2550-6978 E-ISSN 2550-696X © 2022.

Corresponding author: Sawarkar, P.; Email: drsuple.punam@gmail.com

Manuscript submitted: 27 Nov 2021, Manuscript revised: 09 Feb 2022, Accepted for publication: 18 March 2022

Haridradigana will also be prescribed to the patients followed by *Basti Karma* to improve its effectiveness and efficacy. The primary objectives of this study is to assess the efficacy of *Haridradi Gana Yoga Basti* with *Haridradi Ghana Vati* over objective parameters i.e. Blood sugar levels (Fasting & Post Prandial), Urine Sugar level, HbA1c in patients with Diabetes Mellitus Type II, to assess the efficacy of Metformin over objective parameters i.e. Blood sugar levels (Fasting & Post Prandial), Urine Sugar level, HbA1c in Diabetes Mellitus Type II& to compare the efficacy of *Haridradigana Yoga Basti* with *Haridradigana Ghana Vati* and Metformin over objective parameters i.e. Blood sugar levels (Fasting & Post Prandial), Urine Sugar level, HbA1c in Diabetes Mellitus Type II. A total of 60 patients will be enrolled by randomly dividing them equally into 2 groups i.e. Tab.Metformin will be prescribed to Group A(Control) for consecutive 45 days & *Yoga Basti* with *Haridradi Gana* (8 days) followed by *Haridradigana Ghana Vati* for GroupB (Trial Group)for 37 day. Changes in the objective parameters i.e., Fasting and Post Prandial Blood Sugar Level, Urine Sugar Level, HbA1cwill be observed and recorded. Results and conclusion will be drawn according to the data obtained in case registration and follow up forms.

Keywords: *Prameha*, diabetes mellitus type II, *Yogvasti*, *Hardidradi Gana*, Metformin.

Introduction

Diabetes mellitus (DM) is a metabolic condition caused by a problem with insulin secretion, action, or both. Insulin insufficiency causes chronic hyperglycemia, resulting in problems with carbohydrate, lipid, and protein metabolism¹. Changing eating routine propensities, way of life change, uneven eating regimen, abundance inexpensive food, absence of activity are the purposes for improvement of development of diabetes and it's root is in urbanization. According to the International Diabetes Federation (IDF), the number of persons with type 2 diabetes mellitus (T2DM) in the globe will rise to 552 million by 2030, more than doubling from 2000². In *Ayurvedic* texts, *Prameha* shows identical Characteristic features which is observed with syndrome of Diabetes Mellitus. *Premea* is a syndrome that encompasses all clinical diseases marked by an increase in urine volume, either with or without an increase in micturition frequency. The two most prominent symptoms of its sick state are polyuria and turbidity of urine³. Oral hypoglycemic specialists and insulin utilized for the treatment of diabetes mellitus by the allopathic arrangement of medication have various incidental effects. *Ayurveda* due to its comprehensive methodology not just intends to accomplish severe glycemic control yet in addition treat underlying driver of the infection.

Background and rationale

In *Ayurveda*, *Acharya Charaka* has additionally grouped *Prameha* under; *Sthula* (Obese) and *Krishna* (Asthenic) based on body constitution; while *Acharya Sushruta*

has grouped it under; *Sahaja* (Genetic) and *Apathya Nimittaja* (Acquired) based on etiological factor included. *Sthula Pramehi* and *Apathya Nimittaja Pramehi* gives the brief look at Type 2 diabetes so we can associate it with NIDDM where weighty food and inactive way of life are the causative components. *Vagbhata* has arranged *Madhumeha* into two classifications as *Dhatukshayajanya Madhumeha* and *Avaranajanya Madhumeha*. The variables which incite Vata straightforwardly cause *Apatarpanajanya Madhumeha* and the variables which incite *Kapha* also, *Pitta* cause *Santarpanajanya Madhumeha*. In the previous kind the patients are generally asthenia can be connected with Type I DM and in the last kind patients are stout and can be likened with Type II DM⁴. Evasion of neatness and exercise, extravagance in resting, lying and stationary propensities and whatever different variables are probably going to increment *Kapha*, fat and pee are the causative components of *Prameha*. As per the Modern science, two kind of Diabetes are alluded to as type I (insulin subordinate) and type II (noninsulin subordinate). Diabetes Mellitus is a gathering of metabolic infection, described by Hyperglycemia coming about because of deformities in insulin discharge, insulin activity or both. Typically, blood glucose level is firmly constrained by insulin, a chemical created by the Pancreas. In patients with diabetes, the nonappearance or lacking creation of insulin causes hyperglycemia. It modifies digestion of Carbohydrate, proteins and fat in the body. It is portrayed by undeniable degree of blood glucose and ensuing discharges through pee. The main side effects of established hypoglycemic drugs consists of weight gain, gastrointestinal (GI) disturbances, liver injury, hypersensitivity reactions, flatulence, diarrhoea and abdominal bloating etc⁵. *Ayurveda* regards patient as entire and never treats sickness yet unhealthy one. So here we are putting venture forward to discover protected and viable medication to control diabetes with having no incidental effect Based on a thorough evaluation of the literature, herbal pharmaceutical interventions and *Panchakarma* procedures, as well as lifestyle changes, have been demonstrated to be helpful and safe in the treatment of diabetes mellitus. Considering the limitations & side effects of the conventional treatment options for DM, it becomes highly imperative to search some alternative but safe and effective treatment modalities in *Ayurveda*. *Ayurveda* can give better administration to *Prameha* without unsafe incidental effects. In *Ayurveda*, 20 kinds of *Prameha* and is a sub-sort of *Vatika Prameha*. The *Vata* might be incited either straight by its etiological factors, by *Avarana* of *Kapha* and *Pitta* to *Vayu* or by *Dhatukshaya*. More emphasis should be given over *Bastichikitsa* among *Panchakarma* having multi-dimensional therapeutic approach and its non-invasive nature as compared to *Vamana* and *Virechana*. *Haridradi Gana* possess *Kapha-medho Ghana* properties that is described in *Ashtangaharidya Sutrasthana ShodhanadiganasangrahnayeAdhaya*⁶. Properties of each drug of *Haridradigana* is mentioned in table no.1. This study will compare the efficiency of *Haridradigana* Yoga Basti with *Haridradigana Ghana Vati* with Metformin in the management of diabetes mellitus type II in order to discover a new combination of Ayurvedic herbs in the current era of ever-growing diabetes mellitus.

Aims and objectives

Aim: Evaluation of the comparative efficacy of *Haridradigana* Yoga Basti with *Haridradigana Ghana Vati* and Metformin in the management of Diabetes Mellitus Type II (*Prameha*).

Objectives:

- To assess the efficacy of *Haridradigana Yoga Basti* with *Haridradigana Ghana Vati* over objective parameters i.e. Blood sugar levels (Fasting & Post Prandial), Urine Sugar level, HbA1c in Diabetes Mellitus Type II
- To assess the efficacy of Metformin over objective parameters i.e. Blood sugar levels (Fasting & Post Prandial), Urine Sugar level, HbA1c in Diabetes Mellitus Type II
- To compare the efficacy of *Haridradigana Yoga Basti* with *Haridradigana Ghana Vati* and Metformin over objective parameters i.e. Blood sugar levels (Fasting & Post Prandial), Urine Sugar level, HbA1c in Diabetes Mellitus Type II

Material and Methods

Study Type: Interventional Study

Trial design:

Superiority clinical trial i.e. A randomized control trial (RCT) – Randomized reference standard control open clinical trial

Case definition: Diagnosed cases of Prameha (Diabetes Type II)

Diagnostic Criteria

Objective parameters:

- Fasting and Post Prandial Blood Sugar Level.
- Urine Sugar Level
- HbA1c

Research question

Whether *Haridradigana Yoga Basti with Haridradigana Ghana Vati* is more efficacious than standard control drug Metformin in the management of Diabetes Mellitus Type II (*Prameha*)?

Ethics and dissemination: Institutional Ethical clearance certificate, obtained with Ref No. MGACH/ IEC/ Oct 2020/128 dated 24.07.2021. CTRI registration is under process.

Methodology

Study Setting: The study will be conducted in Panchakarma OPD & IPD, Mahatma Gandhi Ayurveda College Hospital and Research Centre (MGACH&RC), Salod (Hirapur) Wardha, Maharashtra.

Eligibility criteria

Inclusion criteria:

- Patients with either sex having age between 20 -60 years
- Patients recently diagnosed for uncomplicated NIDDM (type 2 diabetes) and having

- ✧ Fasting blood sugar level ≥ 126 mg/dl⁷
- ✧ Post meal blood sugar level ≥ 140 mg/dl
- ✧ HbA1c ≥ 6.5 ⁸
- Old cases of type-2 DM not taking any other anti-hypoglycaemic drugs
- Diabetic Patients suffering from Controlled Hypertension (Blood Pressure not more than ≥ 140 mmHg or an average Diastolic Blood Pressure not more than ≥ 90 mmHg)
- Patients willing to give informed consent
- Patient fit for *Basti Karma* as per the *Ayurvedic* classics⁹

Exclusion criteria

- Patients with insulin-dependent diabetes mellitus (IDDM) and Type 2 diabetes who are on insulin therapy
- Patients suffering from Juvenile Diabetes or Gestational diabetes (ICD – 10 criteria 024)
- DM with complications e.g. Retinopathy, Nephropathy, neuropathy, previous history of coma
- Patients suffering from any current acute illness, uncontrolled hypertension

Interventions

- Group A(Control)- Tab. Metformin
- Group B(Trial): *Yoga Basti* with *Haridradi Gana* (8 days) followed by *Haridravigana Ghana Vati*

Methodology: Methodology of the study is depicted in table no.4. The Study design is given in figure no.1

Criteria for discontinuing or modifying allocated interventions:

- Patients willing to quit in between will be allowed to quit and will be replaced.
- If patient develops any acute illness during the trial which may hamper the study.
- Withdrawn patients will be replaced.
- If any untoward incidence, features of drug sensitivity or any other disease or problem arises, the subject will be offered free treatment till the problem subsides.

Follow up: 45th day, 90th day

Assessment Criteria

Objective parameters:

- Fasting and Post Prandial Blood Sugar Level.
- Urine Sugar Level
- HbA1c

Outcomes:

Primary: Primary outcome is reduction in clinical features related to Prameha (Diabetes Type II)

Participant timeline: Total 90 days with follow up on 45th and 90th day.

Methods: Assignment of interventions (for controlled trials)

Total Sample size- 60 Patients (30 in each group) [considering 10 % drop out in each group]

Data collection, management, and analysis methods

Observations will be made after completion of study, according to the data collected with the help of following:

- Case registration Form with detailed history and examination
- Follow Up Assessment Performa

Observations will be made according to the Data collected and subjected to statistical analyses to draw the results.

Data monitoring: The Data coding will be done by PI.

Statistical methods: Data obtained will be calculated by using Student's Paired and Unpaired 't' test. Data on continuous variables will be analysed using parametric tests. The data on discrete variables will be presented as (%). The continuous data will be presented as mean (SD)/Median (Min-Max). A p value of less than 0.05 will be considered as significant.

Consent: The written informed consent will be taken from the patient before starting the study. During the study the confidentiality of each patient will be maintained.




Figure 1. Flowchart of study design or methodology

Table 1
Properties/Rasapanchak of herbs of Haridradi Gana

Serial No.	Drug	Rasa	Vipak	Virya	Guna	Mahabhuta
1	Haridra	Katu, Tikta	Katu	Ushna	Laghu, Ruksha	Vayu, Agni, Akaash
2	Daruharidra	Tikta, Kashaya	Katu	Ushna	Laghu, Ruksha	Vaayu, Akaash, Prithvi
3	Yashtimadhu	Madhura	Madhura	Sheeta	Guru, Snigdha	Pruthvi, Jala
4	Prushnaparni	Madhura, Kashaya	Madhura	Sheeta	Laghu, Snigdha	Pruthvi, Jala
5	Indrauyava	Tikta, Kashaya	Katu	Ushna	Laghu, Ruksha	Vayu, Akaash

Table 2
Methodology of the study

S.N.	Head	Group A (Control)	Group B (Trial)
1	Sample size	30	30
2	Intervention	Tab. Metformin	<i>Yoga Basti with Haridradigana</i> Followed by <i>Haridradigana Ghana Vati</i>
3	Duration of treatment	45 days (1½Months)	8 days, 37 days
4	Schedules	1-90 days	1 st day <i>Anuvasana Basti</i> 2 nd day <i>Niruha Basti</i> Alternate
5	Follow up period	90 th day	47 th day
6	Total duration	90 days	8 days
7	Dose	500mg OD	<i>Anuvasana Basti</i> - 60ml <i>Niruha Basti</i> - 774ml ²³
8	Preparation and Procedure	Tab. Metformin 500mg Orally once a day	1. <i>Poorva Karma</i> (a) <i>Basti Dravya</i> preparation (b) <i>Snehana</i> (c) <i>Swedana</i> 2. <i>Pradhana Karma</i> (a) The patient should lie in the <i>Vama Parshva</i> (Left Lateral) position. (b) The <i>BastiNetra</i> is then put into the <i>Gudamarga</i> (Anus), and the <i>Basti Dravya</i> is delivered in a slow and steady manner.. 3. <i>Paschaat Karma</i>²⁴ (a) The patient is allowed to lie down for a few minutes in a supine position. (b) <i>Snana</i> (Bath) (c) <i>Rasadi Samsarjana Karma</i>

Discussion

According to *Samprapti* of *Prameha*, *Dosha* vitiation i.e. mainly *Kapha* takes place in *Basti* (Urinary Bladder) and it disturbs the *Vata Dosha*. Due to *Vata Dosha*, *Kapha* moves in whole body and induces Obstruction in *Basti*¹⁰. Under the *Samprapti* of *Santarpanajanya Prameha* or in *Sthula Pramehi* the vitiated *Kapha*

and *Pitta* deter the Path of *Vata* causing its incitement. *Shodhana* is the favoured decision for the disposal of *Doshas*. *Acharya Sushruta* has especially referenced that in *Prameha* the vitiated *Doshas* stays arranged in the lower some portion of the body inferable from the failure of different *Dhamanis* for example vessels. *Avaranajanya Prameha*, *Kapha* is the dominating *Dosha* while the significant *Dushyas* are *Meda* and *Kleda*¹¹. In *Avaranajanya Samprapti* the vitiated *Kapha* and *Pitta* hinder the way of *Vata* causing its incitement. *Samshodhana* is effective treatment for disposal of *doshas*. *Vagbhata* has referenced that *Doshas* ought to be wiped out through the closest section¹². The viability of treatment is evaluated dependent on alleviation in cardinal signs and side effects likewise glucose, lipid profile, and other bio-synthetic boundaries with *Deha bala*, *Agni bala*, and *Chitta bala* according to Charak¹³. *Basti Karma* in highly indicated by ancient *Acharyas* to counter and pacify such vitiated *VataDosha*¹⁴. *Kapha Doshaghna* herbs should be selected for *Vasti* to mitigate *Kapha*. In this study, *Haridradi Gana* ¹⁵is selected for *Niruha Basti*. All five drugs in *Haridradi Gana* have *Kapha-Ghana* properties as shown in table no.1¹⁶. After *Yoga Basti* schedule completion, then *Vati* prepared by same *HaridradiGana* will be given for oral administration. *Haridradi Gana* is an ideal blend of medications which can clear *Agnimandya*

What's more, do *Sroto shodhana* as most of the medications are *Laghu* in *Paka* and *Ushna Veerya*. The extremely subsequent stage in *Samprapthi Vighatana* is giving *Preenana* and *Poshana*. *Haridradi Gana* is having drugs like *Prishniparni* and *Yashtimadhu* which are *Madhura Vipaka* which does the last capacity. *Usna Veerya Katu Vipaka* drugs are known for *Srotoshodhana*, *AgniVardhana*, *Ama Pachana*, *Vatanulomana*. These credits helps in clearing the *Sroto Sanga*, trailed by *Jataragni* and *Rasa Dhatwagni Vardhana* which thus helps in *Rasa dhatu* and its *Upadhatu Nirmana* and *Poshana*. So, use of *HaridradiGana* through both Anal& oral routes will enhance the *Kapha-Medoghana* effect of the therapy. The probable mode of action of each drug in *HaridradiGana* based on their Anti-diabetic properties can be justified as follows:

Haridra (Curcuma longa): Curcumin reduces blood glucose and glycosylated haemoglobin levels by inhibiting hepatic glucose production and glycogen synthesis and stimulates glucose absorption by raising the expression of the genes Glucose Transporter1, Glucose Transporter2, and Glucose Transporter3¹⁷. In Ayurvedic writing, powder of *Haridra* is exhorted in diabetes alongside *Amlaki churna* and nectar. It ends up being better dietary enhancement of high likely when utilized with milk. Curcuminoids lower lipid peroxidation by keeping up with the exercises of cancer prevention agent proteins like superoxide dismutase, catalase and glutathione peroxidase at more significant level. *Curcuma longa* contains curcuminoids, glycosides, terpenoides and flavanoids. Maximal hindrance of Human Pancreatic Amylase (HPA) was gotten from isopropanol remove what's more, CH₃)₂CO remove which diminishes starch hydrolysis¹⁸.

Daruharidra (Berberis aristata): The anti-hyperglycemic activity of *Daruharidra* root extract and its involvement in carbohydrate metabolism were investigated in diabetic rats, and it was discovered that it dramatically decreases blood glucose without having any hypoglycemic effect on their control counterparts¹⁹.

Yashtimadhu (*Glycyrrhiza glabra*): The diabetogenic effects of streptozotocin were significantly improved by glycyrrhizin treatment, which modulated blood glucose levels, glucose intolerant behaviour, decreased serum insulin levels, including pancreatic islet cell numbers, increased glycohaemoglobin levels, and increased cholesterol and triglyceride levels²⁰.

Prushnaparni (*Urariapicta*): The amount of *U. picta* given to the animals on a regular diet significantly improved their glucose clearance rates. Future studies should look at the increased quantity because the insulin sensitivity of plant extracts is yet unknown²¹

Indrayava (*Holarrhena antidysenterica*): The effects of Indrayava extract on streptozotocin-induced diabetes in rats. Indrayava seeds reduced serum blood glucose levels in diabetic rats in 14 and 21 days, lowering glucose levels by 39.7% and 48.0%, respectively²²⁻⁴⁰.

Conclusion

Conclusion(s) will be drawn according to the observations made in the case registration and follow up forms on the various assessment parameters.

References

1. Bastaki S. Diabetes mellitus and its treatment. *Int. J. Diabetes Metab.* 2005;13(3):111-34.
2. IDF Diabetes Atlas -International Diabetes Federation. 2011. Available at:<https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.htm>. Accessed on 10 February 2018
3. VagbhataAstangaHridayamNidanasthana chapter No. 10/7,Vagbhata, AstangaHridayam with Vidyotinihindi commentary of kavirajAtridevagupt; Editor yadunandanupadhyayChaukambhaOrientalia; Varanasi; Reprint 2018, pg no.495
4. VagbhataAstangaHridayamNidanasthana chapter No. 10/18-19,Vagbhata, AstangaHridayam with Vidyotinihindi commentary of kavirajAtridevagupt; Editor yadunandanupadhyayChaukambhaOrientalia; Varanasi; Reprint 2018, pg no.497
5. Bastaki S. Diabetes mellitus and its treatment. *Int. J. Diabetes Metab.* 2005;13(3):111-34.
6. VagbhataAstangaHridayamNidanasthana chapter No.15/35-36,Vagbhata, AstangaHridayam with Vidyotinihindi commentary of kavirajAtridevagupt; Editor yadunandanupadhyayChaukambhaOrientalia; Varanasi; Reprint 2018, pg. no.201
7. <https://www.who.int/data/gho/indicator-metadata-registry/imr-details/2380>
8. https://www.who.int/diabetes/publications/report-hba1c_2011.pdf
9. VagbhataAstangaHridayamSutrasthanachapter No.19/6, Vagbhata, AstangaHridayam with Vidyotinihindi commentary of kavirajAtridevagupt; Editor yadunandanupadhyayChaukambhaOrientalia; Varanasi; Reprint 2018, pg. no.231

10. VagbhataAstangaHridayam*Nidanasthanachapter* No.10/4-5, Vagbhata, AstangaHridayam with Vidyotinihindi commentary of kavirajAtridevagupt; Editor yadunandanupadhyayChaukambhaOrientalia; Varanasi; Reprint 2018, pg. no.494
11. Acharya Sushruta: Sushruta Samhita with Nibandhasangraha commentary by Dalhanacharya, edited by Vaidya Yadavji Trikamji Acharya & Narayan Ram Acharya "Kavyathirtha", Published by- Chaukhambha Orientalia, Varanasi, 8th Edition 2005; Chikitsasthana chapter no. 12/8, pg. no.456
12. VagbhataAstangaHridayam Sutrasthana chapter No.13/29, Vagbhata, AstangaHridayam with Vidyotinihindi commentary of kavirajAtridevagupt; Editor yadunandanupadhyayChaukambhaOrientalia; Varanasi; Reprint 2018, pg. no.188
13. Acharya Agnivesha: Charaka Samhita with Ayurveda Dipika commentary of Chakrapanidatta, edited by Vaidya Yadavji Trikamji Acharya, Published by- Chaukhambha Surbharati Prakashan, Varanasi, Reprint Edition 2000, *Vimanasthana* Chapter 8, pg. no. 615
14. VagbhataAstangaHridayamSutrasthanachapter No.19/1, Vagbhata, AstangaHridayam with
15. Vidyotinihindi commentary of kavirajAtridevagupt; Editor yadunandanupadhyayChaukambhaOrientalia; Varanasi; Reprint 2018, pg. no.227
16. VagbhataAstangaHridayam*Nidanasthana* chapter No.15/35-36,Vagbhata, AstangaHridayam with Vidyotinihindi commentary of kavirajAtridevagupt; Editor yadunandanupadhyayChaukambhaOrientalia; Varanasi; Reprint 2018, pg. no.201
17. Sharma P.Dravyagunavigyam,Vol. 2; 1993. Delhi, India:Chaukhamba Publications
18. Ghorbani Z, Hekmatdoost A, Mirmiran P. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. International journal of endocrinology and metabolism. 2014 Oct;12(4)
19. Pandey, M.M.(1995), Septic wounds in diabetic & role of herbal treatment, Sachitra Ayurveda, Vol-48(3), pp392-394
20. Singh J ,Kakkar p. Antihyperglycemic& antioxidant effect of Berberisaristata root extract & it's role in regulating carbohydrate metabolism in diabetic rats. J Ethanopharmacology 2009 May 4 . 123 [1]: 22-6
21. Sen S, Roy M, Chakraborti AS. Ameliorative effects of glycyrrhizin on streptozotocin-induced diabetes in rats.Journal of Pharmacy and Pharmacology. 2011 Feb;63(2):287-96
22. Fatokun FK, Danckwerts MP, Crowther N. Oral glucose tolerance of traditional medicines in a diabetes induced rat model. Int J PharmacognosyPhytochem Res. 2012;4:41-
23. VinaykumarPathakHolarrhenaantidysenterica seeds against streptozotocin induced Diabetic in rats. International journal of pharma research & review, April 2015. 4[4]: 1-6
24. Vagbhata. AstangaHridaya (Sarvangasundara& Ayurveda rasayana commentaries by Arunadatta&Hemadri). HarisastrParadakara, editor. Varanasi: Caukhamba Sanskrit Sansthan; 2014.Sutra sthana,19/45. p.278

25. Vagbhata. AstaangaHridaya (Sarvangasundara& Ayurveda rasayana commentaries by Arunadatta&Hemadri). HarisastrisParadakara, editor. Varanasi: Caukhamba Sanskrit Sansthan; 2014.Sutra sthana,19/45. p.278
26. James SL, Castle CD, Dingels ZV, Fox JT, Hamilton EB, Liu Z, Roberts NL, Sylte DO, Bertolacci GJ, Cunningham M, Henry NJ. Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. *Injury Prevention*. 2020 Oct 1;26(Suppl 2):i125-53.
27. Kumar A, Chery L, Biswas C, Dubhashi N, Dutta P, Dua VK, Kacchap M, Kakati S, Khandeparkar A, Kour D, Mahajan SN. Malaria in South Asia: prevalence and control. *Acta tropica*. 2012 Mar 1;121(3):246-55.
28. Chole RH, Patil RN, Basak A, Palandurkar K, Bhowate R. Estimation of serum malondialdehyde in oral cancer and precancer and its association with healthy individuals, gender, alcohol, and tobacco abuse. *Journal of cancer research and therapeutics*. 2010 Oct 1;6(4):487.
29. Pradhan S, Madke B, Kabra P, Singh AL. Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology. *Indian journal of dermatology*. 2016 Sep;61(5):469.
30. Acharya S, Shukla S, Mahajan SN, Diwan SK. Acute dengue myositis with rhabdomyolysis and acute renal failure. *Annals of Indian Academy of Neurology*. 2010 Jul;13(3):221.
31. Gadbail AR, Chaudhary M, Patil S, Gawande M. Actual Proliferating Index and p53 protein expression as prognostic marker in odontogenic cysts. *Oral Diseases*. 2009 Oct;15(7):490-8.
32. Prasad N, Bhatt M, Agarwal SK, Kohli HS, Gopalakrishnan N, Fernando E, Sahay M, Rajapurkar M, Chowdhary AR, Rath M, Jeloka T. The adverse effect of COVID pandemic on the care of patients with kidney diseases in India. *Kidney international reports*. 2020 Sep 1;5(9):1545-50.
33. Walia IS, Borle RM, Mehendiratta D, Yadav AO. Microbiology and antibiotic sensitivity of head and neck space infections of odontogenic origin. *Journal of maxillofacial and oral surgery*. 2014 Mar 1;13(1):16-21.
34. Lohe VK, Degwekar SS, Bhowate RR, Kadu RP, Dangore SB. Evaluation of correlation of serum lipid profile in patients with oral cancer and precancer and its association with tobacco abuse. *Journal of oral pathology & medicine*. 2010 Feb;39(2):141-8.
35. Korde S, Sridharan G, Gadbail A, Poornima V. Nitric oxide and oral cancer: A review. *Oral oncology*. 2012 Jun 1;48(6):475-83.
36. Gondivkar SM, Gadbail AR. Gorham-Stout syndrome: a rare clinical entity and review of literature. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*. 2010 Feb 1;109(2):e41-8.
37. Gadbail AR, Chaudhary M, Gawande M, Hande A, Sarode S, Tekade SA, Korde S, Zade P, Bhowate R, Borle R, Patil S. Oral squamous cell carcinoma in the background of oral submucous fibrosis is a distinct clinicopathological entity with better prognosis. *Journal of Oral Pathology & Medicine*. 2017 Jul;46(6):448-53.
38. Gadre PK, Ramanojam S, Patankar A, Gadre KS. Nonvascularized bone grafting for mandibular reconstruction: myth or reality?. *Journal of Craniofacial Surgery*. 2011 Sep 1;22(5):1727-35.

39. Sorte K, Sune P, Bhake A, Shivkumar VB, Gangane N, Basak A. Quantitative assessment of DNA damage directly in lens epithelial cells from senile cataract patients. *Molecular vision*. 2011;17:1.
40. Basak S, Rajurkar MN, Mallick SK. Detection of *Blastocystis hominis*: a controversial human pathogen. *Parasitology research*. 2014 Jan;113(1):261-5.